This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Correction

Correction: Long-Term Outcome of Adolescent Depression

Benedetto Vitiello, MD; Graham Emslie, MD; Gregory Clarke, PhD; Karen Dineen Wagner, MD, PhD; Joan R. Asarnow, PhD; Martin B. Keller, MD; Boris Birmaher, MD; Neal D. Ryan, MD; Betsy Kennard, PsyD; Taryn L. Mayes, MS; Lynn DeBar, PhD; Frances Lynch, PhD; John Dickerson, PhD; Michael Strober, PhD; Robert Suddath, MD; James T. McCracken, MD; Anthony Spirito, PhD; Matthew Onorato, LCSW; Jamie Zelazny, MPH, RN; Giovanna Porta, MS; Satish Iyengar, PhD; and David A. Brent, MD

Published: October 23, 2019

Correction

In the article “Long-Term Outcome of Adolescent Depression Initially Resistant to Selective Serotonin Reuptake Inhibitor Treatment: A Follow-Up Study of the TORDIA Sample,” by Benedetto Vitiello, MD, and colleagues, published in the March 2011 issue (J Clin Psychiatry 2011;72[3]:388-396), the SIQ-Jr mean score at 72 weeks on page 391 should be about 10, the number of youths who attempted suicide and had a SIQ-Jr score above 31, indicative of elevated suicidal risk, on pages 392 and 394 should be 2, and the y-axis labels in both parts of Figure 4 should range from 5 to 35. The authors state that because the magnitude of differences in the SIQ-Jr is unchanged, none of the errors affects the interpretation of the results or conclusions. The online version of the article has been corrected.

Volume: 80

Quick Links: Depression (MDD)

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...